Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Hong Kong-based Ascletis Pharma announced today positive interim results from the first two cohorts of its randomized, double ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

The $630m agreement includes an upfront payment, as well as development and commercial milestones ... GLP-1RA drug ...

Trump directed a panel headed by HHS Secretary Robert F. Kennedy Jr. to assess “the prevalence of and threat” posed by SSRIs, ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...

The company created its GLP-1 Insurance Checker specifically to help you determine your coverage on popular weight loss drugs like Ozempic, Wegovy, and Zepbound. If you're new to Ro, they'll even ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

There are many reasons, but the most important is reduced reimbursement for prescription drugs. Most community pharmacies operate under a business model centered on dispensing medications that relies ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

The latest investor updates on stocks that are trending on Wednesday.